Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Medical Management of Pancreatic Neuroendocrine Tumors in Patients With Men 1: Case Report Publisher



Mohajeritehrani MR1 ; Ebrahimpur M2 ; Nasserimoghaddam S3 ; Tavangar SM4 ; Sani MP1 ; Zandi A5 ; Shadmehr MB6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Elderly Health Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Digestive Disease Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Pathology, Tehran Medical University of Medical Sciences, Tehran, Iran
  5. 5. Fellowship of bariatric surgery, Atiyeh Hospital, Tehran, Iran
  6. 6. Tracheal Diseases Research Center (TDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Journal of Diabetes and Metabolic Disorders Published:2022


Abstract

Objectives: Multiple endocrine neoplasia type 1 (MEN-1) is a rare inherited autosomal dominant disease which manifests itself with at least one clinical scenario before 45 years of age. The value of somatostatin analogue therapy is unknown in the treatment of non-functioning pancreatic tumours and a few studies have been published in this field. Case presentation: We report a young patient with MEN-1 with multiple gastric and pancreatic neuroendocrine tumors that was treated with the monthly injection of Sandostatin LAR before and After Distal Pancreatectomy and partial gastrectomy. Conclusions: Now she is well after four years of treatment with Sandostatin LAR. © 2022, The Author(s), under exclusive licence to Tehran University of Medical Sciences.